カテゴリー： LP Information, 世界, 医療/バイオ

世界の希少疾患治療薬市場予測 2021年-2026年

【英語タイトル】Global Rare Disease Drug Market Growth 2021-2026

LP Informationが出版した調査資料（LPI21MY9563）・商品コード：LPI21MY9563
・発行会社（調査会社）：LP Information
・発行日：2021年5月（※2024年版があります。お問い合わせください）
・ページ数：184
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥541,680見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥812,520見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,083,360見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
LPインフォメーション社の「希少疾患治療薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、1‰以上、0.65‰〜1‰、0.1‰以下など、用途別には、病院薬局、専門薬局、小売薬局、その他などにセグメント区分してまとめました。希少疾患治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・希少疾患治療薬の世界市場概要（サマリー）
・希少疾患治療薬の企業別販売量・売上
・希少疾患治療薬の企業別市場シェア
・希少疾患治療薬の世界市場規模 2016年-2021年：種類別（1‰以上、0.65‰〜1‰、0.1‰以下）
・希少疾患治療薬の世界市場規模 2016年-2021年：用途別（病院薬局、専門薬局、小売薬局、その他）
・希少疾患治療薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど）
・希少疾患治療薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）
・希少疾患治療薬のヨーロッパ市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・希少疾患治療薬の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）
・希少疾患治療薬市場の成長要因・課題・動向
・希少疾患治療薬の世界市場予測 2021年-2026年
・希少疾患治療薬の南北アメリカ市場予測（アメリカ、カナダ、メキシコなど）
・希少疾患治療薬のアジア市場予測（日本、中国、韓国、インド、東南アジアなど）
・希少疾患治療薬のヨーロッパ市場予測（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・希少疾患治療薬の中東・アフリカ市場予測（エジプト、南アフリカ、トルコ、GCC諸国など）
・希少疾患治療薬の世界市場予測：種類別（1‰以上、0.65‰〜1‰、0.1‰以下）
・希少疾患治療薬の世界市場予測：用途別（病院薬局、専門薬局、小売薬局、その他）
・主要企業分析
【レポートの概要】

According to this latest study, the 2020 growth of Rare Disease Drug will have significant change from previous year. By the most conservative estimates of global Rare Disease Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Rare Disease Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Rare Disease Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Above 1‰
0.65‰～1‰
Below 0.1‰

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Takeda
Amgen, Inc.
Deciphera
Atara Biotherapeutics
ProQR

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Rare Disease Drug Consumption 2016-2026
2.1.2 Rare Disease Drug Consumption CAGR by Region
2.2 Rare Disease Drug Segment by Type
2.2.1 Above 1‰
2.2.2 0.65‰～1‰
2.2.3 Below 0.1‰
2.3 Rare Disease Drug Sales by Type
2.3.1 Global Rare Disease Drug Sales Market Share by Type (2016-2021)
2.3.2 Global Rare Disease Drug Revenue and Market Share by Type (2016-2021)
2.3.3 Global Rare Disease Drug Sale Price by Type (2016-2021)
2.4 Rare Disease Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Speciality Pharmacies
2.4.3 Retail pharmacies
2.4.4 Others
2.5 Rare Disease Drug Sales by Application
2.5.1 Global Rare Disease Drug Sale Market Share by Application (2016-2021)
2.5.2 Global Rare Disease Drug Revenue and Market Share by Application (2016-2021)
2.5.3 Global Rare Disease Drug Sale Price by Application (2016-2021)

3 Global Rare Disease Drug by Company
3.1 Global Rare Disease Drug Sales Market Share by Company
3.1.1 Global Rare Disease Drug Sales by Company (2019-2021)
3.1.2 Global Rare Disease Drug Sales Market Share by Company (2019-2021)
3.2 Global Rare Disease Drug Revenue Market Share by Company
3.2.1 Global Rare Disease Drug Revenue by Company (2019-2021)
3.2.2 Global Rare Disease Drug Revenue Market Share by Company (2019-2021)
3.3 Global Rare Disease Drug Sale Price by Company
3.4 Global Manufacturers Rare Disease Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Rare Disease Drug Product Location Distribution
3.4.2 Players Rare Disease Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Rare Disease Drug by Region
4.1 Global Rare Disease Drug by Region
4.1.1 Global Rare Disease Drug Sales by Region
4.1.2 Global Rare Disease Drug Revenue by Region
4.2 Americas Rare Disease Drug Sales Growth
4.3 APAC Rare Disease Drug Sales Growth
4.4 Europe Rare Disease Drug Sales Growth
4.5 Middle East & Africa Rare Disease Drug Sales Growth

5 Americas
5.1 Americas Rare Disease Drug Sales by Country
5.1.1 Americas Rare Disease Drug Sales by Country (2016-2021)
5.1.2 Americas Rare Disease Drug Revenue by Country (2016-2021)
5.2 Americas Rare Disease Drug Sales by Type
5.3 Americas Rare Disease Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Rare Disease Drug Sales by Region
6.1.1 APAC Rare Disease Drug Sales by Region (2016-2021)
6.1.2 APAC Rare Disease Drug Revenue by Region (2016-2021)
6.2 APAC Rare Disease Drug Sales by Type
6.3 APAC Rare Disease Drug Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Rare Disease Drug by Country
7.1.1 Europe Rare Disease Drug Sales by Country (2016-2021)
7.1.2 Europe Rare Disease Drug Revenue by Country (2016-2021)
7.2 Europe Rare Disease Drug Sales by Type
7.3 Europe Rare Disease Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Rare Disease Drug by Country
8.1.1 Middle East & Africa Rare Disease Drug Sales by Country (2016-2021)
8.1.2 Middle East & Africa Rare Disease Drug Revenue by Country (2016-2021)
8.2 Middle East & Africa Rare Disease Drug Sales by Type
8.3 Middle East & Africa Rare Disease Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Rare Disease Drug Distributors
10.3 Rare Disease Drug Customer

11 Global Rare Disease Drug Market Forecast
11.1 Global Rare Disease Drug Forecast by Region
11.1.1 Global Rare Disease Drug Forecast by Regions (2021-2026)
11.2.2 Global Rare Disease Drug Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Rare Disease Drug Forecast by Type
11.7 Global Rare Disease Drug Forecast by Application

12 Key Players Analysis
12.1 Novartis AG
12.1.1 Novartis AG Novartis AG Company Information
12.1.2 Novartis AG Rare Disease Drug Product Offered
12.1.3 Novartis AG Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Novartis AG Main Business Overview
12.1.5 Novartis AG Latest Developments
12.2 Bristol-Myers Squibb Company
12.2.1 Bristol-Myers Squibb Company Company Information
12.2.2 Bristol-Myers Squibb Company Rare Disease Drug Product Offered
12.2.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Bristol-Myers Squibb Company Main Business Overview
12.2.5 Bristol-Myers Squibb Company Latest Developments
12.3 Celgene Corporation
12.3.1 Celgene Corporation Company Information
12.3.2 Celgene Corporation Rare Disease Drug Product Offered
12.3.3 Celgene Corporation Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Celgene Corporation Main Business Overview
12.3.5 Celgene Corporation Latest Developments
12.4 F. Hoffmann-La Roche Ltd.
12.4.1 F. Hoffmann-La Roche Ltd. Company Information
12.4.2 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Offered
12.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 F. Hoffmann-La Roche Ltd. Main Business Overview
12.4.5 F. Hoffmann-La Roche Ltd. Latest Developments
12.5 Pfizer, Inc.
12.5.1 Pfizer, Inc. Company Information
12.5.2 Pfizer, Inc. Rare Disease Drug Product Offered
12.5.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Pfizer, Inc. Main Business Overview
12.5.5 Pfizer, Inc. Latest Developments
12.6 Sanofi S.A.
12.6.1 Sanofi S.A. Company Information
12.6.2 Sanofi S.A. Rare Disease Drug Product Offered
12.6.3 Sanofi S.A. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Sanofi S.A. Main Business Overview
12.6.5 Sanofi S.A. Latest Developments
12.7 Alexion Pharmaceuticals, Inc.
12.7.1 Alexion Pharmaceuticals, Inc. Company Information
12.7.2 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Offered
12.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Alexion Pharmaceuticals, Inc. Main Business Overview
12.7.5 Alexion Pharmaceuticals, Inc. Latest Developments
12.8 Eli Lilly and Company
12.8.1 Eli Lilly and Company Company Information
12.8.2 Eli Lilly and Company Rare Disease Drug Product Offered
12.8.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Eli Lilly and Company Main Business Overview
12.8.5 Eli Lilly and Company Latest Developments
12.9 Novo Nordisk A/S
12.9.1 Novo Nordisk A/S Company Information
12.9.2 Novo Nordisk A/S Rare Disease Drug Product Offered
12.9.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Novo Nordisk A/S Main Business Overview
12.9.5 Novo Nordisk A/S Latest Developments
12.10 AstraZeneca
12.10.1 AstraZeneca Company Information
12.10.2 AstraZeneca Rare Disease Drug Product Offered
12.10.3 AstraZeneca Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.10.4 AstraZeneca Main Business Overview
12.10.5 AstraZeneca Latest Developments
12.11 Eisai Co., Ltd.
12.11.1 Eisai Co., Ltd. Company Information
12.11.2 Eisai Co., Ltd. Rare Disease Drug Product Offered
12.11.3 Eisai Co., Ltd. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.11.4 Eisai Co., Ltd. Main Business Overview
12.11.5 Eisai Co., Ltd. Latest Developments
12.12 Daiichi Sankyo Company Limited
12.12.1 Daiichi Sankyo Company Limited Company Information
12.12.2 Daiichi Sankyo Company Limited Rare Disease Drug Product Offered
12.12.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.12.4 Daiichi Sankyo Company Limited Main Business Overview
12.12.5 Daiichi Sankyo Company Limited Latest Developments
12.13 Bayer AG
12.13.1 Bayer AG Company Information
12.13.2 Bayer AG Rare Disease Drug Product Offered
12.13.3 Bayer AG Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.13.4 Bayer AG Main Business Overview
12.13.5 Bayer AG Latest Developments
12.14 GlaxoSmithKline
12.14.1 GlaxoSmithKline Company Information
12.14.2 GlaxoSmithKline Rare Disease Drug Product Offered
12.14.3 GlaxoSmithKline Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.14.4 GlaxoSmithKline Main Business Overview
12.14.5 GlaxoSmithKline Latest Developments
12.15 Merck & Co., Inc.
12.15.1 Merck & Co., Inc. Company Information
12.15.2 Merck & Co., Inc. Rare Disease Drug Product Offered
12.15.3 Merck & Co., Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.15.4 Merck & Co., Inc. Main Business Overview
12.15.5 Merck & Co., Inc. Latest Developments
12.16 Johnson & Johnson
12.16.1 Johnson & Johnson Company Information
12.16.2 Johnson & Johnson Rare Disease Drug Product Offered
12.16.3 Johnson & Johnson Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.16.4 Johnson & Johnson Main Business Overview
12.16.5 Johnson & Johnson Latest Developments
12.17 Biogen, Inc.
12.17.1 Biogen, Inc. Company Information
12.17.2 Biogen, Inc. Rare Disease Drug Product Offered
12.17.3 Biogen, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.17.4 Biogen, Inc. Main Business Overview
12.17.5 Biogen, Inc. Latest Developments
12.18 Takeda
12.18.1 Takeda Company Information
12.18.2 Takeda Rare Disease Drug Product Offered
12.18.3 Takeda Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.18.4 Takeda Main Business Overview
12.18.5 Takeda Latest Developments
12.19 Amgen, Inc.
12.19.1 Amgen, Inc. Company Information
12.19.2 Amgen, Inc. Rare Disease Drug Product Offered
12.19.3 Amgen, Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.19.4 Amgen, Inc. Main Business Overview
12.19.5 Amgen, Inc. Latest Developments
12.20 Deciphera
12.20.1 Deciphera Company Information
12.20.2 Deciphera Rare Disease Drug Product Offered
12.20.3 Deciphera Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.20.4 Deciphera Main Business Overview
12.20.5 Deciphera Latest Developments
12.21 Atara Biotherapeutics
12.21.1 Atara Biotherapeutics Company Information
12.21.2 Atara Biotherapeutics Rare Disease Drug Product Offered
12.21.3 Atara Biotherapeutics Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.21.4 Atara Biotherapeutics Main Business Overview
12.21.5 Atara Biotherapeutics Latest Developments
12.22 ProQR
12.22.1 ProQR Company Information
12.22.2 ProQR Rare Disease Drug Product Offered
12.22.3 ProQR Rare Disease Drug Sales, Revenue, Price and Gross Margin (2019-2021)
12.22.4 ProQR Main Business Overview
12.22.5 ProQR Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Rare Disease Drug Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Above 1‰
Table 3. Major Players of 0.65‰～1‰
Table 4. Major Players of Below 0.1‰
Table 5. Global Rare Disease Drug Sales by Type (2016-2021) & (K Doses)
Table 6. Global Rare Disease Drug Sales Market Share by Type (2016-2021)
Table 7. Global Rare Disease Drug Revenue by Type (2016-2021) & ($ million)
Table 8. Global Rare Disease Drug Revenue Market Share by Type (2016-2021)
Table 9. Global Rare Disease Drug Sale Price by Type (2016-2021)
Table 10. Global Rare Disease Drug Sales by Application (2016-2021) & (K Doses)
Table 11. Global Rare Disease Drug Sales Market Share by Application (2016-2021)
Table 12. Global Rare Disease Drug Value by Application (2016-2021)
Table 13. Global Rare Disease Drug Revenue Market Share by Application (2016-2021)
Table 14. Global Rare Disease Drug Sale Price by Application (2016-2021)
Table 15. Global Rare Disease Drug Sales by Company (2019-2021) & (K Doses)
Table 16. Global Rare Disease Drug Sales Market Share by Company (2019-2021)
Table 17. Global Rare Disease Drug Revenue by Company (2019-2021) ($ Millions)
Table 18. Global Rare Disease Drug Revenue Market Share by Company (2019-2021)
Table 19. Global Rare Disease Drug Sale Price by Company (2019-2021)
Table 20. Key Manufacturers Rare Disease Drug Producing Area Distribution and Sales Area
Table 21. Players Rare Disease Drug Products Offered
Table 22. Rare Disease Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Rare Disease Drug Sales by Region (2016-2021) (K Doses)
Table 26. Global Rare Disease Drug Sales Market Share by Region (2016-2021)
Table 27. Global Rare Disease Drug Revenue by Region (2016-2021) & ($ Millions)
Table 28. Global Rare Disease Drug Revenue Market Share by Region (2016-2021)
Table 29. Americas Rare Disease Drug Sales by Country (2016-2021) & (K Doses)
Table 30. Americas Rare Disease Drug Sales Market Share by Country (2016-2021)
Table 31. Americas Rare Disease Drug Revenue by Country (2016-2021) & ($ Millions)
Table 32. Americas Rare Disease Drug Revenue Market Share by Country (2016-2021)
Table 33. Americas Rare Disease Drug Sales by Type (2016-2021) & (K Doses)
Table 34. Americas Rare Disease Drug Sales Market Share by Type (2016-2021)
Table 35. Americas Rare Disease Drug Sales by Application (2016-2021) & (K Doses)
Table 36. Americas Rare Disease Drug Sales Market Share by Application (2016-2021)
Table 37. APAC Rare Disease Drug Sales by Region (2016-2021) & (K Doses)
Table 38. APAC Rare Disease Drug Sales Market Share by Region (2016-2021)
Table 39. APAC Rare Disease Drug Revenue by Region (2016-2021) & ($ Millions)
Table 40. APAC Rare Disease Drug Revenue Market Share by Region (2016-2021)
Table 41. APAC Rare Disease Drug Sales by Type (2016-2021) & (K Doses)
Table 42. APAC Rare Disease Drug Sales Market Share by Type (2016-2021)
Table 43. APAC Rare Disease Drug Sales by Application (2016-2021) & (K Doses)
Table 44. APAC Rare Disease Drug Sales Market Share by Application (2016-2021)
Table 45. Europe Rare Disease Drug Sales by Country (2016-2021) & (K Doses)
Table 46. Europe Rare Disease Drug Sales Market Share by Country (2016-2021)
Table 47. Europe Rare Disease Drug Revenue by Country (2016-2021) & ($ Millions)
Table 48. Europe Rare Disease Drug Revenue Market Share by Country (2016-2021)
Table 49. Europe Rare Disease Drug Sales by Type (2016-2021) & (K Doses)
Table 50. Europe Rare Disease Drug Sales Market Share by Type (2016-2021)
Table 51. Europe Rare Disease Drug Sales by Application (2016-2021) & (K Doses)
Table 52. Europe Rare Disease Drug Sales Market Share by Application (2016-2021)
Table 53. Middle East & Africa Rare Disease Drug Sales by Country (2016-2021) & (K Doses)
Table 54. Middle East & Africa Rare Disease Drug Sales Market Share by Country (2016-2021)
Table 55. Middle East & Africa Rare Disease Drug Revenue by Country (2016-2021) & ($ Millions)
Table 56. Middle East & Africa Rare Disease Drug Revenue Market Share by Country (2016-2021)
Table 57. Middle East & Africa Rare Disease Drug Sales by Type (2016-2021) & (K Doses)
Table 58. Middle East & Africa Rare Disease Drug Sales Market Share by Type (2016-2021)
Table 59. Middle East & Africa Rare Disease Drug Sales by Application (2016-2021) & (K Doses)
Table 60. Middle East & Africa Rare Disease Drug Sales Market Share by Application (2016-2021)
Table 61. Global Rare Disease Drug Sales Forecast by Type (2021-2026) & (K Doses)
Table 62. Global Rare Disease Drug Sales Market Share Forecast by Type (2021-2026)
Table 63. Global Rare Disease Drug Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 64. Global Rare Disease Drug Revenue Market Share Forecast by Type (2021-2026)
Table 65. Global Rare Disease Drug Sales Forecast by Application (2021-2026) & (K Doses)
Table 66. Global Rare Disease Drug Sales Market Share Forecast by Application (2021-2026)
Table 67. Global Rare Disease Drug Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 68. Global Rare Disease Drug Revenue Market Share Forecast by Application (2021-2026)
Table 69. Novartis AG Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 70. Novartis AG Rare Disease Drug Product Offered
Table 71. Novartis AG Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 72. Novartis AG Main Business
Table 73. Novartis AG Latest Developments
Table 74. Bristol-Myers Squibb Company Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Bristol-Myers Squibb Company Rare Disease Drug Product Offered
Table 76. Bristol-Myers Squibb Company Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 77. Bristol-Myers Squibb Company Main Business
Table 78. Bristol-Myers Squibb Company Latest Developments
Table 79. Celgene Corporation Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Celgene Corporation Rare Disease Drug Product Offered
Table 81. Celgene Corporation Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 82. Celgene Corporation Main Business
Table 83. Celgene Corporation Latest Developments
Table 84. F. Hoffmann-La Roche Ltd. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Offered
Table 86. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 87. F. Hoffmann-La Roche Ltd. Main Business
Table 88. F. Hoffmann-La Roche Ltd. Latest Developments
Table 89. Pfizer, Inc. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer, Inc. Rare Disease Drug Product Offered
Table 91. Pfizer, Inc. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 92. Pfizer, Inc. Main Business
Table 93. Pfizer, Inc. Latest Developments
Table 94. Sanofi S.A. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Sanofi S.A. Rare Disease Drug Product Offered
Table 96. Sanofi S.A. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 97. Sanofi S.A. Main Business
Table 98. Sanofi S.A. Latest Developments
Table 99. Alexion Pharmaceuticals, Inc. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Offered
Table 101. Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 102. Alexion Pharmaceuticals, Inc. Main Business
Table 103. Alexion Pharmaceuticals, Inc. Latest Developments
Table 104. Eli Lilly and Company Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Eli Lilly and Company Rare Disease Drug Product Offered
Table 106. Eli Lilly and Company Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 107. Eli Lilly and Company Main Business
Table 108. Eli Lilly and Company Latest Developments
Table 109. Novo Nordisk A/S Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Novo Nordisk A/S Rare Disease Drug Product Offered
Table 111. Novo Nordisk A/S Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 112. Novo Nordisk A/S Main Business
Table 113. Novo Nordisk A/S Latest Developments
Table 114. AstraZeneca Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. AstraZeneca Rare Disease Drug Product Offered
Table 116. AstraZeneca Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 117. AstraZeneca Main Business
Table 118. AstraZeneca Latest Developments
Table 119. Eisai Co., Ltd. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Eisai Co., Ltd. Rare Disease Drug Product Offered
Table 121. Eisai Co., Ltd. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 122. Eisai Co., Ltd. Main Business
Table 123. Eisai Co., Ltd. Latest Developments
Table 124. Daiichi Sankyo Company Limited Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Daiichi Sankyo Company Limited Rare Disease Drug Product Offered
Table 126. Daiichi Sankyo Company Limited Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 127. Daiichi Sankyo Company Limited Main Business
Table 128. Daiichi Sankyo Company Limited Latest Developments
Table 129. Bayer AG Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 130. Bayer AG Rare Disease Drug Product Offered
Table 131. Bayer AG Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 132. Bayer AG Main Business
Table 133. Bayer AG Latest Developments
Table 134. GlaxoSmithKline Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 135. GlaxoSmithKline Rare Disease Drug Product Offered
Table 136. GlaxoSmithKline Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 137. GlaxoSmithKline Main Business
Table 138. GlaxoSmithKline Latest Developments
Table 139. Merck & Co., Inc. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 140. Merck & Co., Inc. Rare Disease Drug Product Offered
Table 141. Merck & Co., Inc. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 142. Merck & Co., Inc. Main Business
Table 143. Merck & Co., Inc. Latest Developments
Table 144. Johnson & Johnson Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 145. Johnson & Johnson Rare Disease Drug Product Offered
Table 146. Johnson & Johnson Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 147. Johnson & Johnson Main Business
Table 148. Johnson & Johnson Latest Developments
Table 149. Biogen, Inc. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 150. Biogen, Inc. Rare Disease Drug Product Offered
Table 151. Biogen, Inc. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 152. Biogen, Inc. Main Business
Table 153. Biogen, Inc. Latest Developments
Table 154. Takeda Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 155. Takeda Rare Disease Drug Product Offered
Table 156. Takeda Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 157. Takeda Main Business
Table 158. Takeda Latest Developments
Table 159. Amgen, Inc. Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 160. Amgen, Inc. Rare Disease Drug Product Offered
Table 161. Amgen, Inc. Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 162. Amgen, Inc. Main Business
Table 163. Amgen, Inc. Latest Developments
Table 164. Deciphera Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 165. Deciphera Rare Disease Drug Product Offered
Table 166. Deciphera Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 167. Deciphera Main Business
Table 168. Deciphera Latest Developments
Table 169. Atara Biotherapeutics Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 170. Atara Biotherapeutics Rare Disease Drug Product Offered
Table 171. Atara Biotherapeutics Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 172. Atara Biotherapeutics Main Business
Table 173. Atara Biotherapeutics Latest Developments
Table 174. ProQR Basic Information, Rare Disease Drug Manufacturing Base, Sales Area and Its Competitors
Table 175. ProQR Rare Disease Drug Product Offered
Table 176. ProQR Rare Disease Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2021E)
Table 177. ProQR Main Business
Table 178. ProQR Latest Developments
List of Figures
Figure 1. Picture of Rare Disease Drug
Figure 2. Rare Disease Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Rare Disease Drug Sales Growth Rate 2016-2026 (K Doses)
Figure 7. Global Rare Disease Drug Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Rare Disease Drug Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Above 1‰
Figure 10. Product Picture of 0.65‰～1‰
Figure 11. Product Picture of Below 0.1‰
Figure 12. Global Rare Disease Drug Sales Market Share by Type in 2020
Figure 13. Global Rare Disease Drug Revenue Market Share by Type (2016-2021)
Figure 14. Rare Disease Drug Consumed in Hospital Pharmacies
Figure 15. Global Rare Disease Drug Market: Hospital Pharmacies (2016-2021) & (K Doses)
Figure 16. Rare Disease Drug Consumed in Speciality Pharmacies
Figure 17. Global Rare Disease Drug Market: Speciality Pharmacies (2016-2021) & (K Doses)
Figure 18. Rare Disease Drug Consumed in Retail pharmacies
Figure 19. Global Rare Disease Drug Market: Retail pharmacies (2016-2021) & (K Doses)
Figure 20. Rare Disease Drug Consumed in Others
Figure 21. Global Rare Disease Drug Market: Others (2016-2021) & (K Doses)
Figure 22. Global Rare Disease Drug Sales Market Share by Application (2016-2021)
Figure 23. Global Rare Disease Drug Revenue Market Share by Application in 2020
Figure 24. Global Rare Disease Drug Revenue Market by Company in 2020 ($ Million)
Figure 25. Global Rare Disease Drug Revenue Market Share by Company in 2020
Figure 26. Global Rare Disease Drug Sales Market Share by Regions (2016-2021)
Figure 27. Global Rare Disease Drug Revenue Market Share by Region in 2020
Figure 28. Americas Rare Disease Drug Sales 2016-2021 (K Doses)
Figure 29. Americas Rare Disease Drug Revenue 2016-2021 ($ Millions)
Figure 30. APAC Rare Disease Drug Sales 2016-2021 (K Doses)
Figure 31. APAC Rare Disease Drug Revenue 2016-2021 ($ Millions)
Figure 32. Europe Rare Disease Drug Sales 2016-2021 (K Doses)
Figure 33. Europe Rare Disease Drug Revenue 2016-2021 ($ Millions)
Figure 34. Middle East & Africa Rare Disease Drug Sales 2016-2021 (K Doses)
Figure 35. Middle East & Africa Rare Disease Drug Revenue 2016-2021 ($ Millions)
Figure 36. Americas Rare Disease Drug Sales Market Share by Country in 2020
Figure 37. Americas Rare Disease Drug Revenue Market Share by Country in 2020
Figure 38. Americas Rare Disease Drug Sales Market Share by Type in 2020
Figure 39. Americas Rare Disease Drug Sales Market Share by Application in 2020
Figure 40. United States Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 41. Canada Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 42. Mexico Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 43. Brazil Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 44. APAC Rare Disease Drug Sales Market Share by Region in 2020
Figure 45. APAC Rare Disease Drug Revenue Market Share by Regions in 2020
Figure 46. APAC Rare Disease Drug Sales Market Share by Type in 2020
Figure 47. APAC Rare Disease Drug Sales Market Share by Application in 2020
Figure 48. China Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 49. Japan Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 50. Korea Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 51. Southeast Asia Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 52. India Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 53. Australia Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 54. Europe Rare Disease Drug Sales Market Share by Country in 2020
Figure 55. Europe Rare Disease Drug Revenue Market Share by Country in 2020
Figure 56. Europe Rare Disease Drug Sales Market Share by Type in 2020
Figure 57. Europe Rare Disease Drug Sales Market Share by Application in 2020
Figure 58. Germany Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 59. France Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 60. UK Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 61. Italy Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 62. Russia Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 63. Middle East & Africa Rare Disease Drug Sales Market Share by Country in 2020
Figure 64. Middle East & Africa Rare Disease Drug Revenue Market Share by Country in 2020
Figure 65. Middle East & Africa Rare Disease Drug Sales Market Share by Type in 2020
Figure 66. Middle East & Africa Rare Disease Drug Sales Market Share by Application in 2020
Figure 67. Egypt Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 68. South Africa Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 69. Israel Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 70. Turkey Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 71. GCC Country Rare Disease Drug Revenue Growth 2016-2021 ($ Millions)
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles


★調査レポート[世界の希少疾患治療薬市場予測 2021年-2026年] (コード：LPI21MY9563)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の希少疾患治療薬市場予測 2021年-2026年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の永久希土類磁石市場予測 2021年-2026年
    LPI21MY2186 / LP Information / 2021年5月 / LPインフォメーション社の「永久希土類磁石の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、ネオジム磁石、サマリウム磁石など、用途別には、工業用、家庭用電化製品、家電製品、自動車、風力タービン、医療機器、航空宇宙などにセグメント区分してまとめました。永久希土類磁石のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・永久希土類磁石の世界市場概要（サマリー） ・永久希土類磁石の企業別販売量・売上 ・永久希土類磁石の企業別市場シェア ・永久希土類磁石の世界市場規模 2016年-2021年：種類別（ネオジム磁石、サマリウム磁石） ・永久希土類磁石の世界市場規模 2016年-2021年：用途別（工業用、家庭用電化製品、家電製品、自動車、風力タービン、医療機器、航空宇宙） ・永久希土類磁石の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・永久希土類磁石のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Permanent Rare Earth Magnets will have significant change from previous year. By the most conservative estimates of global Permanent Rare Earth Magnets market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Permanent Rare Earth Magnets market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Permanent Rare Earth Magnets...
  • 世界のハンセン病治療薬市場予測 2021年-2026年
    LPI21MY9549 / LP Information / 2021年5月 / LPインフォメーション社の「ハンセン病治療薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、クロファジミン、サリドマイド、その他など、用途別には、病院、クリニック、その他などにセグメント区分してまとめました。ハンセン病治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・ハンセン病治療薬の世界市場概要（サマリー） ・ハンセン病治療薬の企業別販売量・売上 ・ハンセン病治療薬の企業別市場シェア ・ハンセン病治療薬の世界市場規模 2016年-2021年：種類別（クロファジミン、サリドマイド、その他） ・ハンセン病治療薬の世界市場規模 2016年-2021年：用途別（病院、クリニック、その他） ・ハンセン病治療薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・ハンセン病治療薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Hansen's Disease Therapeutics will have significant change from previous year. By the most conservative estimates of global Hansen's Disease Therapeutics market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Hansen's Disease Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Hansen's Disease Therapeutics market by product type,...
  • 世界の希少糖市場予測 2021年-2026年
    LPI21MY1601 / LP Information / 2021年5月 / LPインフォメーション社の「希少糖の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、栄養補助食品、パーソナルケア、製薬、その他など、用途別には、D-マンノース、L-アラビノース、L-フコース、その他などにセグメント区分してまとめました。希少糖のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・希少糖の世界市場概要（サマリー） ・希少糖の企業別販売量・売上 ・希少糖の企業別市場シェア ・希少糖の世界市場規模 2016年-2021年：種類別（栄養補助食品、パーソナルケア、製薬、その他） ・希少糖の世界市場規模 2016年-2021年：用途別（D-マンノース、L-アラビノース、L-フコース、その他） ・希少糖の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・希少糖のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Rare Sugars will have significant change from previous year. By the most conservative estimates of global Rare Sugars market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Rare Sugars market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Rare Sugars market by product type, application, key manufacturers and...
  • 世界の糖尿病性眼疾患用装置市場予測 2021年-2026年
    LPI21MY8906 / LP Information / 2021年5月 / LPインフォメーション社の「糖尿病性眼疾患用装置の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、レーザー手術、硝子体切除術など、用途別には、病院、クリニック、その他などにセグメント区分してまとめました。糖尿病性眼疾患用装置のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・糖尿病性眼疾患用装置の世界市場概要（サマリー） ・糖尿病性眼疾患用装置の企業別販売量・売上 ・糖尿病性眼疾患用装置の企業別市場シェア ・糖尿病性眼疾患用装置の世界市場規模 2016年-2021年：種類別（レーザー手術、硝子体切除術） ・糖尿病性眼疾患用装置の世界市場規模 2016年-2021年：用途別（病院、クリニック、その他） ・糖尿病性眼疾患用装置の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・糖尿病性眼疾患用装置のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Diabetic Eye Disease Devices will have significant change from previous year. By the most conservative estimates of global Diabetic Eye Disease Devices market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Diabetic Eye Disease Devices market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Eye Disease Devices...
  • 世界のゴーシェ病治療薬市場予測 2021年-2026年
    LPI21MY9538 / LP Information / 2021年5月 / LPインフォメーション社の「ゴーシェ病治療薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、酵素、グルコシルセラミドシンターゼ阻害剤、骨粗鬆症治療薬など、用途別には、I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病などにセグメント区分してまとめました。ゴーシェ病治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・ゴーシェ病治療薬の世界市場概要（サマリー） ・ゴーシェ病治療薬の企業別販売量・売上 ・ゴーシェ病治療薬の企業別市場シェア ・ゴーシェ病治療薬の世界市場規模 2016年-2021年：種類別（酵素、グルコシルセラミドシンターゼ阻害剤、骨粗鬆症治療薬） ・ゴーシェ病治療薬の世界市場規模 2016年-2021年：用途別（I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病） ・ゴーシェ病治療薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・ゴーシェ病治療薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Gaucher Disease Drugs will have significant change from previous year. By the most conservative estimates of global Gaucher Disease Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 1292.3 million in 2019. Over the next five years the Gaucher Disease Drugs market will register a 0.6% CAGR in terms of revenue, the global market size will reach US$ 1326.1 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Gaucher Disease Drugs market by product type,...
  • 世界の超高純度希土類改質アルミナ市場予測 2021年-2026年
    LPI21MY2950 / LP Information / 2021年5月 / LPインフォメーション社の「超高純度希土類改質アルミナの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、5N、 >5Nなど、用途別には、サファイア、リチウム電池ダイヤフラム材料、ハイエンド蛍光体、触媒、半導体セラミック、その他などにセグメント区分してまとめました。超高純度希土類改質アルミナのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・超高純度希土類改質アルミナの世界市場概要（サマリー） ・超高純度希土類改質アルミナの企業別販売量・売上 ・超高純度希土類改質アルミナの企業別市場シェア ・超高純度希土類改質アルミナの世界市場規模 2016年-2021年：種類別（5N、 >5N） ・超高純度希土類改質アルミナの世界市場規模 2016年-2021年：用途別（サファイア、リチウム電池ダイヤフラム材料、ハイエンド蛍光体、触媒、半導体セラミック、その他）...According to this latest study, the 2020 growth of Ultra-High Purity Rare Earth Modified Alumina will have significant change from previous year. By the most conservative estimates of global Ultra-High Purity Rare Earth Modified Alumina market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Ultra-High Purity Rare Earth Modified Alumina market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth...
  • 世界の心血管疾患治療薬市場予測 2021年-2026年
    LPI21MY9466 / LP Information / 2021年5月 / LPインフォメーション社の「心血管疾患治療薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロットレル、その他など、用途別には、虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他などにセグメント区分してまとめました。心血管疾患治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・心血管疾患治療薬の世界市場概要（サマリー） ・心血管疾患治療薬の企業別販売量・売上 ・心血管疾患治療薬の企業別市場シェア ・心血管疾患治療薬の世界市場規模 2016年-2021年：種類別（ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロットレル、その他） ・心血管疾患治療薬の世界市場規模 2016年-2021年：用途別（虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他） ・心血管疾患治療薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・心血管疾患治療薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Cardiovascular Disease Drugs will have significant change from previous year. By the most conservative estimates of global Cardiovascular Disease Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Cardiovascular Disease Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular Disease Drugs market by product type,...
  • 世界のゴセレリン薬市場予測 2021年-2026年
    LPI21MY9545 / LP Information / 2021年5月 / LPインフォメーション社の「ゴセレリン薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、3.6mg、10.8mgなど、用途別には、前立腺がん、乳がん、子宮内膜症、その他などにセグメント区分してまとめました。ゴセレリン薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・ゴセレリン薬の世界市場概要（サマリー） ・ゴセレリン薬の企業別販売量・売上 ・ゴセレリン薬の企業別市場シェア ・ゴセレリン薬の世界市場規模 2016年-2021年：種類別（3.6mg、10.8mg） ・ゴセレリン薬の世界市場規模 2016年-2021年：用途別（前立腺がん、乳がん、子宮内膜症、その他） ・ゴセレリン薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・ゴセレリン薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Goserelin Drug will have significant change from previous year. By the most conservative estimates of global Goserelin Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Goserelin Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Goserelin Drug market by product type, application, key manufacturers and...
  • 世界の疾病検査用口腔液収集チューブ市場予測 2021年-2026年
    LPI21MY9167 / LP Information / 2021年5月 / LPインフォメーション社の「疾病検査用口腔液収集チューブの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、唾液チューブ、口腔スポンジなど、用途別には、一般分析用、ゲノム分析用などにセグメント区分してまとめました。疾病検査用口腔液収集チューブのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・疾病検査用口腔液収集チューブの世界市場概要（サマリー） ・疾病検査用口腔液収集チューブの企業別販売量・売上 ・疾病検査用口腔液収集チューブの企業別市場シェア ・疾病検査用口腔液収集チューブの世界市場規模 2016年-2021年：種類別（唾液チューブ、口腔スポンジ） ・疾病検査用口腔液収集チューブの世界市場規模 2016年-2021年：用途別（一般分析用、ゲノム分析用） ・疾病検査用口腔液収集チューブの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・疾病検査用口腔液収集チューブのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Oral Fluid Collection Tubes for Disease Testing will have significant change from previous year. By the most conservative estimates of global Oral Fluid Collection Tubes for Disease Testing market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Oral Fluid Collection Tubes for Disease Testing market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market...
  • 世界のMRD（最小残存病変）検査市場予測 2021年-2026年
    LPI21MY9126 / LP Information / 2021年5月 / LPインフォメーション社の「MRD（最小残存病変）検査の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）など、用途別には、専門クリニック・病院、診断研究所、研究機関などにセグメント区分してまとめました。MRD（最小残存病変）検査のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・MRD（最小残存病変）検査の世界市場概要（サマリー） ・MRD（最小残存病変）検査の企業別販売量・売上 ・MRD（最小残存病変）検査の企業別市場シェア ・MRD（最小残存病変）検査の世界市場規模 2016年-2021年：種類別（フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）） ・MRD（最小残存病変）検査の世界市場規模 2016年-2021年：用途別（専門クリニック・病院、診断研究所、研究機関） ・MRD（最小残存病変）検査の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・MRD（最小残存病変）検査のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of MRD (Minimal Residual Disease) Testing will have significant change from previous year. By the most conservative estimates of global MRD (Minimal Residual Disease) Testing market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ XX million in 2020. Over the next five years the MRD (Minimal Residual Disease) Testing market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of MRD...

    • ◆H&Iグローバルリサーチのお客様（例）◆